Edition:
United States

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,380JPY
--
Change (% chg)

-- (--)
Prev Close
¥1,380
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
8,147,675
52-wk High
¥1,779
52-wk Low
¥1,338

Select another date:

Fri, Jun 9 2017

BRIEF-Astellas, Pfizer announce amendment to clinical research protocol for phase 3 prosper trial of enzalutamide

* Astellas and Pfizer announce amendment to clinical research protocol for phase 3 prosper trial of enzalutamide in patients with non-metastatic castration-resistant prostate cancer

BRIEF-Seattle Genetics, Astellas announce updated enfortumab vedotin phase 1 data in metastatic urothelial cancer ​

* Trial evaluating enfortumab vedotin in combination with CPIs is also planned for later in the year​

BRIEF- Astellas Pharma completes acquisition of Ogeda SA in Belgium

* Says it has completed the acquisition of Ogeda SA, a drug discovery company located in Gosselies, Belgium, and Ogeda has become a wholly owned subsidiary of the company as of CET May 17

BRIEF- Astellas Pharma to discontinue ASP8273 treatment and close randomization for clinical study protocol 8273-CL-0302

* Says it announced the discontinuation of ASP8273 treatment arm in the the late-stage SOLAR trial evaluating the efficacy and safety of ASP8273 versus erlotinib/gefitinib

BRIEF-Astellas Pharma says transfer of 16 Long-Listed Products in Japan to LTL Pharma

* Says Astellas and LTL Pharma Co., Ltd.confirmed the relevant closing conditions are met on April 28 to allow the transfer of the assets related to Astellas’ 16 long-listed products in Japan to LTL Pharma

BRIEF-Astellas Pharma to retire treasury shares

* Says it will retire 85 million shares( 4 percent of outstanding ) of its common stock on May 31

BRIEF-Astellas Pharma to acquire Ogeda SA

* under agreement, Astellas has agreed to pay up to a total of eur 800 million

BRIEF-RIBOMIC plans joint research agreement with Astellas pharma

* Says it plans to enter into joint research agreement with Astellas pharma Inc, regarding R&D of aptamers pharmaceuticals

BRIEF-X-Chem signs broad drug discovery collaboration with Astellas Pharma

* X-Chem Inc - announced signing of a broad drug discovery collaboration with Astellas Pharma Inc

BRIEF-Astellas and Affinivax announce worldwide partnership for maps vaccine targeting pneumococcal disease

* Says Affinivax, Inc. and Astellas Pharma Inc. entered into an exclusive worldwide license agreement to develop and commercialize a vaccine targeting Streptococcus pneumoniae

Select another date:

More From Around the Web